CoChat

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Cardiorenal Safety of OTC Analgesics

Open access
White, William B., Kloner, Robert A., Angiolillo, Dominick J., Davidson, Michael H. · 2018 · Journal of Cardiovascular Pharmacology and Therapeutics

Abstract

Over-the-counter analgesics are used globally for the relief of acute pain. Although effective, these agents can be associated with adverse effects that may limit their use in some people. In the early 2000s, observations from clinical trials of prescription-strength and supratherapeutic doses of nonselective and cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs (NSAIDs) raised safety concerns regarding the risk of cardiovascular adverse effects with the use of these medications. Subsequently, the US Food and Drug Administration mandated additional study of the cardiovascular safety of NSAIDs for a more comprehensive understanding of their risk. As these data were being collected, and based on a comprehensive review of prescription data and the recommendations of the US Food and Drug Administration Advisory Committee, the warning labels of over-the-counter NSAIDs were updated to emphasize the potential cardiovascular risks of these agents. The recently reported “Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen” (PRECISION) trial, in which participants with osteoarthritis or rheumatoid arthritis and underlying cardiovascular risk factors were treated with prescription-strength celecoxib, ibuprofen, or naproxen, revealed similar rates of cardiovascular events (death from cardiovascular causes including hemorrhagic death, nonfatal myocardial infarction, or nonfatal stroke) among the 3 treatment groups. Although informative, the cardiovascular safety findings derived from PRECISION cannot be extrapolated to the safety of the over-the-counter pain relievers ibuprofen and naproxen, given that the doses used were higher (mean [standard deviation]: ibuprofen, 2045 [246] mg; naproxen, 852 [103] mg) and the durations of use longer (∼20 months) than recommended with over-the-counter use of NSAIDs, which for ibuprofen is up to 10 days. This review discusses the cardiorenal safety of the most commonly used over-the-counter analgesics, ibuprofen, naproxen, and acetaminophen. Available data suggest that there is little cardiovascular risk when over-the-counter formulations of these agents are used as directed in their labels.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/1074248417751070

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Mechanisms of action of traditional and COX-2-selective NSAIDs. Adapted from Brune and Patrignani.37 COX indicates cyclooxygenase; Coxibs, COX-2 inhibitors; GI, gastrointestinal; NSAIDs, nonsteroidal anti-inflammatory drugs; PG, prostaglandin; PGI2, prostacyclin; tNSAIDs, traditional NSAIDs; TxA2, thromboxane.
Figure 1. Mechanisms of action of traditional and COX-2-selective NSAIDs. Adapted from Brune and Patrignani.37 COX indicates cyclooxygenase; Coxibs, COX-2 inhibitors; GI, gastrointestinal; NSAIDs, nonsteroidal anti-inflammatory drugs; PG, prostaglandin; PGI2, prostacyclin; tNSAIDs, traditional NSAIDs; TxA2, thromboxane.CC BY · PubMed Central
Figure 2. Warning labels for OTC (A) or prescription (B) NSAIDs. A, Over-the-counter NSAIDs72: All OTC NSAID Drug Facts Labels are being revised for US FDA approval. New drug safety information will be added to the respective sections as shown. B, Black box warning for prescription-strength naproxen. All prescription NSAIDs carry the same warning.12 FDA indicates Food and Drug Administration; NSAIDs, nonsteroidal anti-inflammatory drugs; OTC, over-the-counter.
Figure 2. Warning labels for OTC (A) or prescription (B) NSAIDs. A, Over-the-counter NSAIDs72: All OTC NSAID Drug Facts Labels are being revised for US FDA approval. New drug safety information will be added to the respective sections as shown. B, Black box warning for prescription-strength naproxen. All prescription NSAIDs carry the same warning.12 FDA indicates Food and Drug Administration; NSAIDs, nonsteroidal anti-inflammatory drugs; OTC, over-the-counter.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Research works printed but not linked: 3

  1. Hirst JJ, 1995, J Clin Endocrinol Metab, 80, 517
  2. Fanelli A, 2013, Acta Biomed, 84, 5
  3. Epstein M, 2002, J Hypertens Suppl, 20, S17

Cited by

See all 32

Metadata

Authors
White, W. B., Kloner, R. A., Angiolillo, D. J., & Davidson, M. H.
Affiliations
  • University of Connecticut (US)
  • University of Southern California (US)
  • University of Florida (US)
  • University of Chicago (US)
Corresponding author
White, William B.
Venue
Journal of Cardiovascular Pharmacology and Therapeutics
Published
2018-02-08
Volume
23
Issue
2
Pages
103-118
ISSN
  • 1074-2484 (ISSN-L)
  • 1940-4034
OpenAlex
W2794398597
Cited by
31
References
55
Citations by year
2025: 2 · 2024: 3 · 2023: 3 · 2022: 4 · 2020: 12 · 2019: 6 · 2018: 1
FWCI
0.55
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Journal of Cardiovascular Pharmacology and Therapeutics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
Keywords
over-the-counter analgesics, nonsteroidal anti-inflammatory drugs, ibuprofen, naproxen, paracetamol, cardiovascular risk, PRECISION trial, celecoxib, drug safety labeling, acute pain relief
MeSH terms
Acetaminophen, Analgesics, Drug Labeling, Nonprescription Drugs, Heart Diseases, Humans, Ibuprofen, Kidney Diseases, Naproxen, Risk Factors, Risk Assessment, Patient Safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cardiorenal Safety of OTC Analgesics. https://app.cochat.ai/papers/10.1177/1074248417751070
The paper
White, W. B., Kloner, R. A., Angiolillo, D. J., & Davidson, M. H. (2018). Cardiorenal Safety of OTC Analgesics. Journal of Cardiovascular Pharmacology and Therapeutics. https://doi.org/10.1177/1074248417751070

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.